Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptinyx Inc. stock logo
APTX
Aptinyx
$0.10
+3.1%
$0.08
$0.01
$0.72
N/A1.271.32 million shs231,100 shs
CORV
Correvio Pharma
$0.42
$0.41
$0.21
$2.79
$27.80M0.085.35 million shsN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.78
$1.91
$1.24
$11.50
$34.25M1.56368,586 shs91,302 shs
KALA BIO, Inc. stock logo
KALA
KALA BIO
$6.92
-0.3%
$7.33
$5.10
$19.35
$19.51M-1.7523,935 shs17,499 shs
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$4.90
+3.6%
$5.10
$4.25
$12.75
$176.65M0.09216,563 shs238,868 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00%0.00%0.00%0.00%+20.00%
CORV
Correvio Pharma
0.00%0.00%0.00%0.00%0.00%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+1.71%+3.49%-4.81%+3.49%-83.80%
KALA BIO, Inc. stock logo
KALA
KALA BIO
-0.96%-0.72%-8.68%-1.00%-54.70%
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
+1.50%+3.28%-5.96%-11.09%-57.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/AN/AN/AN/A
CORV
Correvio Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.002 of 5 stars
3.52.00.00.00.63.30.6
KALA BIO, Inc. stock logo
KALA
KALA BIO
4.1652 of 5 stars
3.55.00.04.42.40.80.0
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.2172 of 5 stars
3.50.00.04.50.61.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/A
CORV
Correvio Pharma
N/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$30.001,585.39% Upside
KALA BIO, Inc. stock logo
KALA
KALA BIO
3.00
Buy$18.00160.12% Upside
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$19.33294.56% Upside

Current Analyst Ratings

Latest FBIO, CORV, APTX, SCPH, and KALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $21.00
4/1/2024
KALA BIO, Inc. stock logo
KALA
KALA BIO
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$15.00
3/19/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/15/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/14/2024
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptinyx Inc. stock logo
APTX
Aptinyx
$1MN/AN/AN/A$0.57 per shareN/A
CORV
Correvio Pharma
$32.63M0.85N/AN/A($0.02) per share-21.00
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$84.51M0.41N/AN/A$0.10 per share17.80
KALA BIO, Inc. stock logo
KALA
KALA BIO
$3.89M5.02N/AN/A$2.79 per share2.48
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
$13.59M13.00N/AN/A$1.04 per share4.71

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptinyx Inc. stock logo
APTX
Aptinyx
-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/A
CORV
Correvio Pharma
-$35.18M-$0.79N/AN/A-107.81%-2,128.82%-58.56%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$60.64M-$8.22N/AN/AN/A-74.12%-770.86%-32.87%5/20/2024 (Estimated)
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$54.81M-$1.42N/AN/AN/A-403.22%-97.18%-49.59%5/8/2024 (Estimated)

Latest FBIO, CORV, APTX, SCPH, and KALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/29/2024Q4 2023
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A-$3.18-$3.18-$3.18N/AN/A
3/28/2024Q4 2023
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/A-$0.53-$0.53-$0.53$14.46 million$19.95 million
3/13/2024Q4 2023
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
-$0.42-$0.35+$0.07-$0.35$6.10 million$6.10 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/A
CORV
Correvio Pharma
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/A
CORV
Correvio Pharma
22.54
1.07
0.95
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
38.42
1.38
1.26
KALA BIO, Inc. stock logo
KALA
KALA BIO
5.10
6.33
6.33
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
1.04
7.08
6.40

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
N/A
CORV
Correvio Pharma
7.30%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
89.52%

Insider Ownership

CompanyInsider Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
10.97%
CORV
Correvio Pharma
N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
33.40%
KALA BIO, Inc. stock logo
KALA
KALA BIO
13.40%
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
4.68%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aptinyx Inc. stock logo
APTX
Aptinyx
12N/AN/ANot Optionable
CORV
Correvio Pharma
13366.19 millionN/AOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
18719.24 million12.81 millionOptionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
432.82 million2.44 millionNot Optionable
scPharmaceuticals Inc. stock logo
SCPH
scPharmaceuticals
13536.05 million34.37 millionOptionable

FBIO, CORV, APTX, SCPH, and KALA Headlines

SourceHeadline
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
globenewswire.com - May 7 at 4:05 PM
scPharmaceuticals Inc. (SCPH) Interactive Stock Chart - Yahoo FinancescPharmaceuticals Inc. (SCPH) Interactive Stock Chart - Yahoo Finance
finance.yahoo.com - April 24 at 11:36 AM
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
markets.businessinsider.com - April 24 at 11:36 AM
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
globenewswire.com - April 24 at 8:00 AM
scPharmaceuticals (NASDAQ:SCPH) Stock Price Down 5.4%scPharmaceuticals (NASDAQ:SCPH) Stock Price Down 5.4%
marketbeat.com - April 18 at 12:40 AM
Novel Biannual Antihypertensive Shows Potential for Combination TherapyNovel Biannual Antihypertensive Shows Potential for Combination Therapy
msn.com - April 10 at 6:08 PM
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
finance.yahoo.com - March 27 at 9:26 AM
scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdatescPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
finanznachrichten.de - March 20 at 6:25 PM
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call TranscriptscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
insidermonkey.com - March 16 at 5:02 PM
SCPH Apr 2024 5.000 putSCPH Apr 2024 5.000 put
finance.yahoo.com - March 16 at 2:28 AM
Buy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial FootingBuy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial Footing
markets.businessinsider.com - March 15 at 4:27 PM
Q4 2023 scPharmaceuticals Inc Earnings CallQ4 2023 scPharmaceuticals Inc Earnings Call
finance.yahoo.com - March 14 at 3:51 PM
Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)
markets.businessinsider.com - March 14 at 10:50 AM
Strong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth ProspectsStrong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth Prospects
markets.businessinsider.com - March 14 at 10:50 AM
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX GrowthscPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth
finance.yahoo.com - March 13 at 6:18 PM
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdatescPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
globenewswire.com - March 13 at 4:01 PM
scPharmaceuticals Q4 2023 Earnings PreviewscPharmaceuticals Q4 2023 Earnings Preview
msn.com - March 12 at 8:33 PM
Craig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)Craig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)
markets.businessinsider.com - March 11 at 6:45 PM
scPharmaceuticals Inc Registered Shs hosts conference call for investorsscPharmaceuticals Inc Registered Shs hosts conference call for investors
markets.businessinsider.com - March 9 at 1:38 PM
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
globenewswire.com - March 6 at 4:01 PM
scPharmaceuticals to Participate in Two Upcoming Investor ConferencesscPharmaceuticals to Participate in Two Upcoming Investor Conferences
globenewswire.com - February 28 at 4:01 PM
scPharmaceuticals Stock (NASDAQ:SCPH), Short Interest ReportscPharmaceuticals Stock (NASDAQ:SCPH), Short Interest Report
benzinga.com - February 21 at 8:00 PM
DelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsightDelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
finanznachrichten.de - January 15 at 5:47 PM
Top 10 stocks with the highest short interest on Wall StreetTop 10 stocks with the highest short interest on Wall Street
msn.com - January 8 at 3:25 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptinyx logo

Aptinyx

NASDAQ:APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Correvio Pharma

NASDAQ:CORV
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Fortress Biotech logo

Fortress Biotech

NASDAQ:FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
KALA BIO logo

KALA BIO

NASDAQ:KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
scPharmaceuticals logo

scPharmaceuticals

NASDAQ:SCPH
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.